Characterization of DNA and MVA vectors expressing Nef from HIV-1 CRF12_BF revealed high immune specificity with low cross-reactivity against subtype B

Virus Research

Volumn 146, Issue 1-2, 2009, Pages 1-12

  Rodriguez A M ^a   Turk, G ^a   Pascutti, M F ^a   Ferrer, F ^b   Najera J L ^c   Monaco D ^a   Esteban, M ^c   Salomon H ^a   Calamante, G ^b   Gherardi, M M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

^c CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

CMI; HIV subtypes; MVA; Nef; Vaccines

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA VECTOR; NEF PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CONTROLLED STUDY; CROSS REACTION; DNA VECTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOFLUORESCENCE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMID; POLYMERASE CHAIN REACTION; POXVIRUS; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS RECOMBINANT; WESTERN BLOTTING;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; CROSS REACTIONS; GENETIC VECTORS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VACCINES, SUBUNIT; VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 70350236509     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.08.004     Document Type: Article

References (53)

1. Aguayo, et al. Epidemiological and molecular characteristics of HIV-1 infection among female commercial sex workers, men who have sex with men and people living with AIDS in Paraguay. Rev. Soc. Bras. Med. Trop. 41 3 (2008) 225-231
2. Betts M.R., et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J. Virol. 71 11 (1997) 8908-8911
3. Brave A., et al. Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology. Infect. Agent. Cancer 2 (2007) 14
4. Buonaguro L., et al. Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J. Virol. 81 19 (2007) 10209-10219
5. Burgers W.A., et al. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J. Gen. Virol. 87 Pt 2 (2006) 399-410
6. Butler I.F., et al. HIV genetic diversity: biological and public health consequences. Curr. HIV Res. 5 1 (2007) 23-45
7. Carr J.K., et al. Diverse BF recombinants have spread widely since the introduction of HIV-1 into South America. AIDS 15 15 (2001) F41-F47
8. Castro E., et al. Molecular epidemiology of HIV-1 in Venezuela: high prevalence of HIV-1 subtype B and identification of a B/F recombinant infection. J. Acquir. Immune Defic. Syndr. 32 3 (2003) 338-344
9. Cazeaux N., et al. Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter. Vaccine 20 27-28 (2002) 3322-3331
10. Currier J.R., et al. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol. 7 (2006) 8
11. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23 6 (1997) 1094-1097
12. Chan K.S., et al. Nef from pathogenic simian immunodeficiency virus is a negative factor for vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 102 24 (2005) 8734-8739
13. Dallo S., and Esteban M. Isolation and characterization of attenuated mutants of vaccinia virus. Virology 159 2 (1987) 408-422
14. Das S.R., and Jameel S. Biology of the HIV Nef protein. Indian J. Med. Res. 121 4 (2005) 315-332
15. De Rose R., et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J. Virol. 81 1 (2007) 292-300
16. De Rose R., et al. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 23 16 (2005) 1949-1956
17. Dilernia D.A., et al. HIV type 1 genetic diversity surveillance among newly diagnosed individuals from 2003 to 2005 in Buenos Aires, Argentina. AIDS Res. Hum. Retroviruses 23 10 (2007) 1201-1207
18. Dorrell L., et al. Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53. Eur. J. Immunol. 31 6 (2001) 1747-1756
19. Earl, P.L., Moss, B., Wyatt, L.S. and Carroll, M.W., 2001. Generation of recombinant vaccinia viruses. Curr. Protoc. Mol Biol. Chapter 16, Unit16 17.
20. Feeney M.E., et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J. Virol. 78 16 (2004) 8927-8930
21. Ferrari G., et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. U.S.A. 94 4 (1997) 1396-1401
22. Gallego-Gomez J.C., et al. Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J. Virol. 77 19 (2003) 10606-10622
23. Geels M.J., et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J .Virol. 79 17 (2005) 11247-11258
24. Gomez-Carrillo M., et al. Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries. AIDS Res. Hum. Retroviruses 22 11 (2006) 1186-1191
25. Gomez Carrillo M., et al. Mother-to-child HIV type 1 transmission in Argentina: BF recombinants have predominated in infected children since the mid-1980s. AIDS Res. Hum. Retroviruses 18 7 (2002) 477-483
26. Gomez C.E., et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25 11 (2007) 1969-1992
27. Goonetilleke N., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol. 80 10 (2006) 4717-4728
28. Goulder P.J., and Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 4 8 (2004) 630-640
29. Hanke T., et al. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88 Pt 1 (2007) 1-12
30. Hemelaar J., et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20 16 (2006) W13-23
31. Hierholzer J., et al. Molecular Epidemiology of HIV Type 1 in Ecuador, Peru, Bolivia, Uruguay, and Argentina. AIDS Res. Hum. Retroviruses 18 18 (2002) 1339-1350
32. Holguin A., et al. Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain. Curr. HIV Res. 6 4 (2008) 327-334
33. Huang Y., et al. Design, construction, and characterization of a dual-promoter multigenic DNA vaccine directed against an HIV-1 subtype C/B' recombinant. J. Acquir. Immune Defic. Syndr. 47 4 (2008) 403-411
34. Janetzki S., et al. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302 (2005) 51-86
35. Lee J.K., et al. T cell cross-reactivity and conformational changes during TCR engagement. J. Exp. Med. 200 11 (2004) 1455-1466
36. Letourneau S., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2 10 (2007) e984
37. Letvin N.L. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6 12 (2006) 930-939
38. Mayr A., et al. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl. Bakteriol. [B] 167 5-6 (1978) 375-390
39. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72 Pt 5 (1991) 1031-1038
40. Najera J.L., et al. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J. Virol. 80 12 (2006) 6033-6047
41. Osmanov S., et al. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J. Acquir. Immune Defic. Syndr. 29 2 (2002) 184-190
42. Quarleri J.F., et al. HIV type 1 BF recombinant strains exhibit different pol gene mosaic patterns: descriptive analysis from 284 patients under treatment failure. AIDS Res. Hum. Retroviruses 20 10 (2004) 1100-1107
43. Ramirez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74 2 (2000) 923-933
44. Risco C., et al. The vaccinia virus 39-kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis. Virology 265 2 (1999) 375-386
45. Rollman E., et al. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model. Vaccine 25 11 (2007) 2145-2154
46. Sierra M., et al. The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF. Infect. Genet. Evol. 5 3 (2005) 209-217
47. Stumptner-Cuvelette P., et al. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl. Acad. Sci. U.S.A. 98 21 (2001) 12144-12149
48. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 89 22 (1992) 10847-10851
49. Thomson M.M., Perez-Alvarez L., and Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect. Dis. 2 8 (2002) 461-471
50. Turk G., et al. Higher transactivation activity associated with LTR and Tat elements from HIV-1 BF intersubtype recombinant variants. Retrovirology 3 (2006) 14
51. Turk G., et al. Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J. Virol. 82 6 (2008) 2853-2866
52. Turk G., et al. Single Nef proteins from HIV type 1 subtypes C and F fail to upregulate invariant chain cell surface expression but are active for other functions. AIDS Res. Hum. Retroviruses 25 3 (2009) 285-296
53. Yamanaka M.K., and Yilma T. Altered plaque formation by recombinant vaccinia virus expressing simian immunodeficiency virus Nef. J. Virol. 72 6 (1998) 5291-5295